Pfizer and Blackstone Agree to Fund Berobenatide Development

Company Pfizer; Blackstone Life Sciences Event Type Development cost-sharing financing (up to $1.5 billion) Modality Long-acting peptide (monthly GLP-1 receptor agonist) Asset Berobenatide Target GLP-1 receptor Disease Area Chronic weight management and related conditions Summary Pfizer announced November 11 that Blackstone-managed funds will cover up…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *